Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Karuna Therapeutics, Inc.

At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. 
 
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
 
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
 
We invite you to join us on LinkedIn and Twitter (@KarunaTx) to stay up to date on our work.

Eventide

Fidelity

Fidelity Management and Research Company

Alexandria Venture Investments

Sands Capital Ventures

Sofinnova Investments

ARCH Venture Partners

Partner Fund Management

Pivotal bioVenture Partners

PureTech Health

Wellcome Trust

Karuna Therapeutics

Today on #February11, we join others around the globe to celebrate International Day of Women and Girls in Science. We especially want to recognize the brilliant women in science on our team. Their leadership and dedication are helping us push the boundaries of innovation in neuroscience, and the best is yet to come! #EquityinScience

Bebe Moore Campbell was a fearless mental health advocate and literary trailblazer who used her words and platform to address the impacts of racism, mental health, culture, and community. This #BlackHistoryMonth, we honor and remember her legacy as well as other Black pioneers who helped shape the #MentalHealth landscape. Learn more about their contributions: https://lnkd.in/dPDdCfR

Schizophrenia is a brain disorder that distorts the way a person thinks, feels, and behaves. While current antipsychotic therapies can help treat some symptoms, such as hallucinations and delusions, they may not fully address symptoms such as memory impairment, decision-making, and the ability to enjoy life – leading to low treatment adherence. Learn more about our commitment to addressing these needs: https://lnkd.in/gmN8ykmx 

Signs and symptoms of #schizophrenia are not “one size fits all.” Schizophrenia symptoms can differ from person to person, but they generally fall into three categories. Learn more about them here: https://lnkd.in/gmN8ykmx 

Wishing you #HappyHolidays from all of us at Karuna! May you find peace and enjoy the company of your loved ones during this season. 

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-6.03M -	-17.51M 190.32%	-43.96M 151.01%	-68.55M 55.96%	-143.81M 109.77%	-276.34M 92.16%	-433.68M 56.94%
depreciation and amortization	1K -	6K 500%	58K 866.67%	145K 150%	506K 248.97%	1.11M 119.76%	1.70M 52.97%
deferred income tax	55K -	444K 707.27%	135K 69.59%
stock based compensation	215K -	958K 345.58%	12.57M 1,211.90%	13.47M 7.18%	29.81M 121.30%	47.45M 59.17%	74.60M 57.21%
change in working capital	563K -	-1.86M 429.66%	599K 132.27%	-15.58M 2,701.00%	10.85M 169.61%	4.77M 55.98%	9.53M 99.56%
accounts receivables					-1.75M -	1.69M 196.74%	57K 96.63%
inventory
accounts payables	537K -	-529K 198.51%	278K 152.55%	318K 14.39%	1.07M 236.79%	243K 77.31%	4.35M 1,688.89%
other working capital	26K -	-1.33M 5,203.85%	321K 124.19%	-15.90M 5,052.65%	11.52M 172.49%	2.84M 75.37%	5.12M 80.51%
other non cash items	1.17M -	2.58M 120.58%	-326K 112.62%	662K 303.07%	1.76M 166.62%	-5.01M 383.68%	-37.97M 658.26%
net cash provided by operating activities	-4.03M -	-15.38M 281.85%	-30.92M 101.10%	-69.86M 125.90%	-100.88M 44.41%	-228.01M 126.02%	-385.82M 69.21%
investments in property plant and equipment	-13K -	-132K 915.38%	-115K 12.88%	-419K 264.35%	-3.07M 633.17%	-915K 70.21%	-2.92M 218.80%
acquisitions net			115K -	419K 264.35%	3.15M 651.55%	1.22M 61.23%	3.92M 221.38%
purchases of investments		-4.98M -	-231.72M 4,550.17%	-344.21M 48.55%	-400.83M 16.45%	-930.28M 132.09%	-1.52B 63.45%
sales maturities of investments			57.50M -	254.98M 343.46%	381.21M 49.51%	344.80M 9.55%	1.36B 295.34%
other investing activites			-115K -	-419K 264.35%	-3.15M 651.55%	-1.22M 61.23%	-3.92M 221.38%
net cash used for investing activites	-13K -	-5.12M 39,246.15%	-174.34M 3,308.31%	-89.65M 48.58%	-22.69M 74.69%	-586.39M 2,484.60%	-160.32M 72.66%
debt repayment			-3.13M -
common stock issued			330.08M -	3.66M 98.89%	270.25M 7,285.90%	819.38M 203.19%	436.72M 46.70%
common stock repurchased							-4.52M -
dividends paid
other financing activites	4.25M -	27.58M 548.87%	78.33M 184.06%		7.33M -	36.40M 396.96%	51.18M 40.59%
net cash used provided by financing activities	4.25M -	27.58M 548.87%	405.28M 1,369.64%	3.66M 99.10%	277.57M 7,486.09%	855.78M 208.30%	483.37M 43.52%
effect of forex changes on cash
net change in cash	210K -	7.08M 3,273.81%	200.03M 2,723.22%	-155.85M 177.91%	154.01M 198.82%	41.38M 73.13%	-62.77M 251.70%
cash at beginning of period	1.73M -	1.94M 12.12%	9.03M 364.83%	209.05M 2,215.85%	53.20M 74.55%	207.21M 289.46%	248.59M 19.97%
cash at end of period	1.94M -	9.03M 364.83%	209.05M 2,215.85%	53.20M 74.55%	207.21M 289.46%	248.59M 19.97%	185.82M 25.25%
operating cash flow	-4.03M -	-15.38M 281.85%	-30.92M 101.10%	-69.86M 125.90%	-100.88M 44.41%	-228.01M 126.02%	-385.82M 69.21%
capital expenditure	-13K -	-132K 915.38%	-115K 12.88%	-419K 264.35%	-3.07M 633.17%	-915K 70.21%	-2.92M 218.80%
free cash flow	-4.04M -	-15.51M 283.89%	-31.04M 100.13%	-70.28M 126.42%	-103.95M 47.92%	-228.92M 120.22%	-388.74M 69.81%

COM:KARUNATX

Karuna Therapeutics, Inc.

Last Close

329.74

15/03 20:00

Market Cap

12.60B

Beta: -

Volume Today

1.28M

Avg: -

Preview